Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Efficacy and Safety of imsidolimab in Participants with Ichthyosis

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • biological: placebo
  • drug: Imsidolimab

Eligibility


Inclusion Criteria:

   - Diagnosis of Ichthyosis

   - IASI total score ≥ 18, erythema score ≥ 2

   - Participant has been using emollient daily for at least 1 week prior to Day 1 and
   agrees to continue using that same emollient daily at the same frequency throughout
   the study

Exclusion Criteria:

   - A participant with ichthyosis vulgaris, X-linked ichthyosis, or lamellar ichthyosis
   will be excluded.

Ages Eligible for Study

12 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
SPECTRUM
650-723-0363
Not Recruiting